Alpha Tau Medical’s (DRTS) “Buy” Rating Reaffirmed at HC Wainwright

Alpha Tau Medical (NASDAQ:DRTS)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued on Friday, Benzinga reports. They currently have a $9.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 300.00% from the stock’s current price.

Separately, Piper Sandler reiterated an “overweight” rating and issued a $7.00 target price on shares of Alpha Tau Medical in a research report on Thursday, August 15th.

Alpha Tau Medical Price Performance

Shares of DRTS stock opened at $2.25 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 11.60 and a current ratio of 11.66. Alpha Tau Medical has a fifty-two week low of $1.75 and a fifty-two week high of $3.90. The firm has a market capitalization of $156.76 million, a price-to-earnings ratio of -5.49 and a beta of 0.77. The stock’s 50-day simple moving average is $2.25 and its 200-day simple moving average is $2.39.

Alpha Tau Medical (NASDAQ:DRTS) last issued its earnings results on Wednesday, August 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. As a group, equities analysts forecast that Alpha Tau Medical will post -0.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alpha Tau Medical

A number of institutional investors have recently modified their holdings of the stock. Levin Capital Strategies L.P. raised its position in Alpha Tau Medical by 2.6% during the first quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company’s stock valued at $999,000 after acquiring an additional 8,641 shares in the last quarter. Caprock Group LLC acquired a new position in shares of Alpha Tau Medical in the second quarter worth about $59,000. Aptus Capital Advisors LLC boosted its position in Alpha Tau Medical by 83.7% during the second quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock worth $56,000 after purchasing an additional 10,000 shares in the last quarter. Financial Guidance Group Inc. lifted its position in shares of Alpha Tau Medical by 83.7% during the 2nd quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock valued at $56,000 after buying an additional 10,000 shares in the last quarter. Finally, USAdvisors Wealth Management LLC acquired a new stake in shares of Alpha Tau Medical in the first quarter valued at about $30,000. Hedge funds and other institutional investors own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.